VeriSIM Life

VeriSIM Life develops an AI-driven drug discovery and development platform called BIOiSIM that uses mechanistic bio-simulation models to predict drug behavior and patient outcomes, enabling pharmaceutical companies to de-risk translational drug development. The platform features a Translational Index that predicts how drugs will affect patients with 83% average accuracy from structure-only inputs, exploring an inferential search space of 1 billion drug-like compounds with 800 billion total potential simulation scenarios. The AtlasGEN Novel Drug Designer identifies new molecules based on favorable chemical properties while simultaneously evaluating clinical safety and effectiveness, supported by a search space of over 1 trillion compounds using generative AI and deep learning. BIOiSIM supports drug repurposing, formulation, drug-drug interactions, safety-toxicity profiles, efficacy predictions, AI drug discovery, and patient stratification. Founded in 2017 and headquartered in San Francisco, the company has raised approximately $21.4M in Series A funding. VeriSIM Life differentiates itself through a formalized research collaboration with FDA/NCTR, an NIH Phase II STTR grant, and its PulmoSIM Therapeutics subsidiary for preclinical translation and out-licensing.